Isomorphic Labs’ release of 17 November: who put in the US$5bn, what its drug design engine does, and the rounds and drugmaker deals before it.
Isomorphic Labs, the London company Alphabet set up in 2021 to design medicines with AI, has raised US$5bn in a Series C round co-led by Greenoaks and Sequoia Capital. Andreessen Horowitz (a16z) and several other new investors joined, Alphabet made what Isomorphic calls “continued significant investment”, and every existing investor took part: Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund.12 Isomorphic describes the round as oversubscribed. It did not disclose a valuation or how much each investor put in.2
It is the company’s third outside round in under 20 months. The first, US$600m in March 2025, was led by Thrive Capital with GV and Alphabet; the second, a US$2.1bn Series B in May 2026, was again led by Thrive, and brought in MGX, Temasek, CapitalG and the UK Sovereign AI Fund.34 Together the three come to US$7.7bn, and the new round is 2.4 times the one closed six months earlier.
US$5bn
Series C, co-led by Greenoaks and Sequoia Capital, announced 17 November
Isomorphic Labs
US$7.7bn
raised in three outside rounds since March 2025
Isomorphic Labs
2.4×
the size of the US$2.1bn Series B of May 2026
Isomorphic Labs
3
drugmakers with research deals: Eli Lilly, Novartis, Johnson & Johnson
Isomorphic Labs
Demis Hassabis announced Isomorphic in November 2021 as “a new Alphabet company” building on DeepMind’s AlphaFold2, the system that predicts a protein’s 3D shape from its amino-acid sequence; he runs it as chief executive, with Max Jaderberg as president.62 Its product is internal: a drug design engine, IsoDDE, a set of AI models meant to work across disease areas and types of drug, from small molecules to antibodies and peptides.29
Isomorphic’s post of 29 September sets out the job it is doing. Conventional screening tests fixed libraries of 100,000 to a billion compounds against a protein, which can take months or years, and turning a hit into a clinical candidate is a multi-year search. Its design agent is given a specification (the target, the kind of molecule, the selectivity and properties wanted) and searches chemical space on a computer for two to four days. Each step of that path, Isomorphic says, traditionally takes one to three months of chemists’ and biologists’ work. A handful of the designs are then made and tested in the lab.5
The release says the work is yielding “positive preclinical results” in its own oncology and immunology programmes and with partners, “setting the stage for clinical entry”. No Isomorphic-designed drug has entered a human trial yet; Hassabis says the round drives “our first therapeutic programs towards clinical trials”. The money also goes on newer biology models, a partner network and the infrastructure to run clinical development.2
Isomorphic’s commercial deals so far are research collaborations with drugmakers. In January 2024 Eli Lilly and Novartis signed collaborations on small-molecule drugs that Isomorphic put at nearly US$3bn if every milestone is met, excluding royalties, with US$45m paid upfront by Lilly and US$37.5m by Novartis.7 Novartis added up to three more programmes in February 2025 on the same financial terms, and Johnson & Johnson signed a multi-target collaboration covering small molecules and biologics in January 2026, with no terms published.89
Isomorphic has raised US$7.7bn since March 2025 and has three drugmaker partners
Funding rounds and research collaborations in Isomorphic Labs’ own announcements, November 2021 to November 2026
| Date | Event | Detail |
|---|---|---|
| Nov 2021 | Isomorphic Labs set up | A new Alphabet company, led by Demis Hassabis |
| Jan 2024 | Lilly and Novartis deals | Up to nearly US$3bn; US$82.5m upfront in all |
| Feb 2025 | Novartis expands | Up to three more programmes, same terms |
| Mar 2025 | US$600m first round | Led by Thrive Capital, with GV and Alphabet |
| Jan 2026 | Johnson & Johnson deal | Multi-target, small molecules and biologics |
| May 2026 | US$2.1bn Series B | Led by Thrive Capital |
| Nov 2026 | US$5bn Series C | Co-led by Greenoaks and Sequoia Capital |
Source: Isomorphic Labs announcements and news releases, 1 November 2021 to 17 November 2026 · as of 17 November 2026
What to watch: the first Isomorphic programme to enter a clinical trial, and whether a fourth drugmaker signs. For another AI company’s round read against what it sells, see Mercor’s US$750m at US$20bn.
Sources
Disclosure. TechBag is a software reseller: it earns when companies buy through it, including from vendors named here. The analysis is TechBag’s own; no vendor paid for or saw this piece before publication. Facts are labelled reported, TechBag count or our view.